GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of GH Research (NASDAQ:GHRS) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $40.00 price target on the stock.

Separately, Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

GH Research Trading Down 0.2 %

NASDAQ:GHRS opened at $8.81 on Monday. The business’s fifty day moving average price is $8.41 and its 200 day moving average price is $8.94. The firm has a market capitalization of $458.37 million, a price-to-earnings ratio of -11.15 and a beta of 0.84. GH Research has a 1-year low of $6.00 and a 1-year high of $14.99.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its position in GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).